# Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

> **NCT00436254** · PHASE1 · COMPLETED · sponsor: **University of Washington** · enrollment: 66 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Stage III Ovarian Epithelial Cancer
- Stage III Ovarian Germ Cell Tumor
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer
- Stage IV Ovarian Epithelial Cancer
- Stage IV Ovarian Germ Cell Tumor

## Interventions

- **BIOLOGICAL:** pNGVL3-hICD vaccine
- **BIOLOGICAL:** sargramostim
- **OTHER:** flow cytometry
- **OTHER:** immunologic technique
- **OTHER:** immunoenzyme technique
- **GENETIC:** protein expression analysis
- **PROCEDURE:** biopsy

## Key facts

- **NCT ID:** NCT00436254
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** 2010-03
- **Final completion:** 2025-04-01
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00436254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00436254, "Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00436254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*